Amgen and UCB's Evenity approved in Japan for osteoporosis

07:22 EST 9 Jan 2019 | Pharmafile

Amgen has revealed that its bone-forming monoclonal antibody Evenity (romosozumab), developed in partnership with UCB Pharma, has been awarded approval in Japan for the treatment of osteoporosis in patients at high risk of fracture.

The decision, which precedes final verdicts in the US and Europe, where review is currently ongoing, was based on Phase 3 data from two studies encompassing 7,180 postmenopausal women and 245 men with osteoporosis, finding the drug to be both safe and effective following a robust review.

Image caption: 
Image Credit: National Osteoporosis Foundation

read more

Original Article: Amgen and UCB's Evenity approved in Japan for osteoporosis


More From BioPortfolio on "Amgen and UCB's Evenity approved in Japan for osteoporosis"

Quick Search


Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Osteoporosis is a disease in which the bones become extremely porous, are subject to fracture, and heal slowly, occurring especially in women following menopause and often leading to curvature of the spine from vertebral collapse. Follow and track&n...

An antibody is a protein produced by the body's immune system when it detects harmful substances, called antigens. Examples of antigens include microorganisms (such as bacteria, fungi, parasites, and viruses) and chemicals. Antibodies may be produc...